Država: Južnoafrička Republika
Jezik: engleski
Izvor: South African Health Products Regulatory Authority (SAHPRA)
Ranbaxy
RANCLAV Suspension RANCLAV Forte Suspension SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): RANCLAV Suspension RANCLAV Forte Suspension COMPOSITION: Ranclav Suspension: Each 5 mL of reconstituted suspension contains: Amoxicillin Trihydrate equivalent to amoxicillin 125 mg and Clavulanate potassium equivalent to clavulanic acid 31,25 mg Sodium benzoate (as preservative) 0,2%m/v Butylated hydroxy toluene(as antioxidant) 0,006% m/v Ranclav Forte Suspension: Each 5 mL of reconstituted suspension contains: Amoxicillin Trihydrate equivalent to amoxicillin 250 mg and Clavulanate potassium equivalent to clavulanic acid 62,5 mg Sodium benzoate (as preservative) 0,2%m/v Butylated hydroxy toluene (as antioxidant) 0,006% m/v PHARMACOLOGICAL CLASSIFICATION: A20.1.2 Penicillins PHARMACOLOGICAL ACTION Mechanism of action: Ranclav is a combination of amoxicillin and potassium clavulanate. The amoxicillin component of the formulation exerts a bactericidal action against many strains of Gram positive and Gram-negative organisms. The clavulanic acid component has little or no antimicrobial action. It does, however, by inactivation of susceptible beta-lactamase protect amoxicillin from degradation by beta-lactamase enzymes produced by penicillin resistant strains of organisms. Antibacterial Activity Clavulanic acid is an irreversible inhibitor of beta-lactamases produced by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris , H. influenzae, N. gonorrhoeae and B. fragilis (In-vitro activity does not necessarily imply in-vivo efficacy). Potassium clavulanate does not inactivate the chromosomally mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinet Pročitajte cijeli dokument